Almirall stock edges lower as investors weigh margin-focused half-year figures

Almirall stock (ISIN ES0157097017) finished the September 18, 2026 session on Bolsa de Madrid at EUR 10.44, marking a decline of 1.51 percent or EUR 0.16 from the prior close and leaving the shares slightly below recent highs as investors continue to weigh the company’s latest margin-focused half-year figures.

Half-year 2026 results highlight revenue and margin trends

According to Almirall in its most recent half-year 2026 report, the dermatology-focused pharmaceutical group reported revenue growth compared with the same period a year earlier, reflecting continued traction in key prescription brands across European markets in the six months to June 30, 2026.

As Almirall outlined, operating performance for the half-year 2026 period showed an improvement in margins versus the comparable half-year of 2025, underpinned by portfolio mix and cost discipline, which the company presented as the basis for its current-year outlook through December 31, 2026.

Stock performance and recent trading context

A recent corporate news overview on Almirall noted that the stock closed at EUR 10.44 on September 18, 2026 on Bolsa de Madrid, down 1.51 percent on the day after a period in which the shares had moved higher on optimism around ongoing margin improvements, with market capitalization reported at roughly EUR 1,900,000,000 as of that date.

Almirall stock price snapshot

On its primary listing on Bolsa de Madrid, Almirall stock closed at EUR 10.44 on September 18, 2026, with a daily decline of 1.51 percent and a price move of EUR minus 0.16 compared with the previous close; based on that closing level, the company’s market capitalization stood at approximately EUR 1,900,000,000 as of September 18, 2026.

More news and analyses on Almirall stock